Head and Neck Cancer
Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III Head and Neck Cancer Study
Published in Lab Business Week, April 29th, 2007
Merck KGaA announced today that a first-line Phase III study of Erbitux(R) (cetuximab) combined with platinum-based chemotherapy met the primary endpoint of increasing overall survival in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This randomized European trial, known as EXTREME (ErbituX in first line Treatment of REcurrent or MEtastatic head & neck cancer), studied more than 400 patients treated with Erbitux in combination with either cisplatin plus 5-fluorouracil (5-FU) or carboplatin plus 5-FU compared with patients treated with cisplatin plus 5-FU or carboplatin plus 5-FU alone.
"Recurring and metastatic head and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2007-04-29)
More Articles from Lab Business Week
- Biomedical Engineering
New biomedical engineering research has been reported by scientists at Abbott Laboratories - Breast Cancer Genetics
Studies from Chester Beatty Laboratories yield new data on breast cancer genetics - Carrington Laboratories, Inc.
Carrington Announces Information in Compliance with NASDAQ Rules - Charles River Laboratories
Charles River Laboratories Schedules First-Quarter 2007 Earnings Release and Conference Call - Drug Development
Pharmatek Opens New Facility - Epilepsy
Study results from Abbott Laboratories broaden understanding of epilepsy - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
